High levels of serum mannose-binding lectins are associated with the severity and clinical outcomes of severe traumatic brain injury

Clinica Chimica Acta

Volumn 451, Issue , 2015, Pages 111-116

  Yu, Wei ^a   Le, Hai Wei ^a   Lu, Yi Gao ^a   Hu, Jun An ^a   Yu, Jian Bo ^b   Wang, Ming ^b   Shen, Wei ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Biomarker; Complement system; Mannose binding lectin; Prognosis; Severity; Traumatic brain injury

Indexed keywords

MANNOSE BINDING LECTIN;

ADULT; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLASGOW COMA SCALE; HUMAN; INJURY SEVERITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SEX RATIO; TRAUMATIC BRAIN INJURY; BLOOD; BRAIN INJURIES; INJURY SCALE; MULTIVARIATE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC;

ADULT; BRAIN INJURIES; FEMALE; HUMANS; MALE; MANNOSE-BINDING LECTINS; MULTIVARIATE ANALYSIS; PROGNOSIS; ROC CURVE; TRAUMA SEVERITY INDICES;

EID: 84946398473     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.10.017     Document Type: Article

References (36)

1. Odgaard L., Poulsen I., Kammersgaard L.P., Johnsen S.P., Nielsen J.F. Surviving severe traumatic brain injury in Denmark: incidence and predictors of highly specialized rehabilitation. Clin. Epidemiol. 2015, 7:225-234.
2. Nonaka M. Evolution of the complement system. Subcell. Biochem. 2014, 80:31-43.
3. Merle N.S., Church S.E., Fremeaux-Bacchi V., Roumenina L.T. Complement system part I - molecular mechanisms of activation and regulation. Front. Immunol. 2015, 6:262.
4. Merle N.S., Noe R., Halbwachs-Mecarelli L., Fremeaux-Bacchi V., Roumenina L.T. Complement system part II: role in immunity. Front. Immunol. 2015, 6:257.
5. Stahel P.F., Morganti-Kossmann M.C., Kossmann T. The role of the complement system in traumatic brain injury. Brain Res. Brain Res. Rev. 1998, 27:243-256.
6. Orsini F., De Blasio D., Zangari R., Zanier E.R., De Simoni M.G. Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. Front. Cell. Neurosci. 2014, 8:380.
7. Scorza M., Liguori R., Elce A., Salvatore F., Castaldo G. Biological role of mannose binding lectin: from newborns to centenarians. Clin. Chim. Acta 2015, (pii: S0009-8981(15)00139-4).
8. Luo J., Xu F., Lu G.J., Lin H.C., Feng Z.C. Low mannose-binding lectin (MBL) levels and MBL genetic polymorphisms associated with the risk of neonatal sepsis: an updated meta-analysis. Early Hum. Dev. 2014, 90:557-564.
9. Huang Q., Shang G., Deng H., Liu J., Mei Y., Xu Y. High mannose-binding lectin serum levels are associated with diabetic retinopathy in Chinese patients with type 2 diabetes. PLoS One 2015, 10.
10. Fildes J.E., Shaw S.M., Walker A.H., McAlindon M., Williams S.G., Keevil B.G., et al. Mannose-binding lectin deficiency offers protection from acute graft rejection after heart transplantation. J. Heart Lung Transplant. 2008, 27:1353-1356.
11. Zhang Z.G., Wang C., Wang J., Zhang Z., Yang Y.L., Gao L., et al. Prognostic value of mannose-binding lectin: 90-day outcome in patients with acute ischemic stroke. Mol. Neurobiol. 2015, 51:230-239.
12. Yager P.H., You Z., Qin T., Kim H.H., Takahashi K., Ezekowitz A.B., et al. Mannose binding lectin gene deficiency increases susceptibility to traumatic brain injury in mice. J. Cereb. Blood Flow Metab. 2008, 28:1030-1039.
13. Longhi L., Orsini F., De Blasio D., Fumagalli S., Ortolano F., Locatelli M., et al. Mannose-binding lectin is expressed after clinical and experimental traumatic brain injury and its deletion is protective. Crit. Care Med. 2014, 42:1910-1918.
14. de la Rosa X., Cervera A., Kristoffersen A.K., Valdés C.P., Varma H.M., Justicia C., et al. Mannose-binding lectin promotes local microvascular thrombosis after transient brain ischemia in mice. Stroke 2014, 45:1453-1459.
15. Morrison H., Frye J., Davis-Gorman G., Funk J., McDonagh P., Stahl G., et al. The contribution of mannose binding lectin to reperfusion injury after ischemic stroke. Curr. Neurovasc. Res. 2011, 8:52-63.
16. Cervera A., Planas A.M., Justicia C., Urra X., Jensenius J.C., Torres F., et al. Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PLoS One 2010, 5.
17. Wang Z.Y., Sun Z.R., Zhang L.M. The relationship between serum mannose-binding lectin levels and acute ischemic stroke risk. Neurochem. Res. 2014, 39:248-253.
18. Osthoff M., Katan M., Fluri F., Schuetz P., Bingisser R., Kappos L., et al. Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. PLoS One 2011, 6.
19. Marshall L.F., Marshall S.B., Klauber M.R., Clark M.V. A new classification of head injury based on computerized tomography. J. Neurosurg. 1991, 75:S14-S20.
20. Jennett B., Bond M. Assessment of outcome after severe brain damage. Lancet 1975, 1:480-484.
21. Guan L.Z., Tong Q., Xu J. Elevated serum levels of mannose-binding lectin and diabetic nephropathy in type 2 diabetes. PLoS One 2015, 10.
22. Brennan F.H., Anderson A.J., Taylor S.M., Woodruff T.M., Ruitenberg M.J. Complement activation in the injured central nervous system: another dual-edged sword?. J. Neuroinflammation 2012, 9:137.
23. Woodruff T.M., Ager R.R., Tenner A.J., Noakes P.G., Taylor S.M. The role of the complement system and the activation fragment C5a in the central nervous system. Neruomol. Med. 2010, 12:179-192.
24. Veerhuis R., Nielsen H.M., Tenner A.J. Complement in the brain. Mol. Immunol. 2011, 48:1592-1603.
25. Harvey H., Durant S. The role of glial cells and the complement system in retinal diseases and Alzheimer's disease: common neural degeneration mechanisms. Exp. Brain Res. 2014, 232:3363-3377.
26. Stephan A.H., Barres B.A., Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci. 2012, 35:369-389.
27. Lettiero B., Andersen A.J., Hunter A.C., Moghimi S.M. Complement system and the brain: selected pathologies and avenues toward engineering of neurological nanomedicines. J. Control. Release 2012, 161:283-289.
28. Alexander J.J., Anderson A.J., Barnum S.R., Stevens B., Tenner A.J. The complement cascade: Yin-yang in neuroinflammation-neuro-protection and-degeneration. J. Neurochem. 2008, 107:1169-1187.
29. Galvan M.D., Luchetti S., Burgos A.M., Nguyen H.X., Hooshmand M.J., Hamers F.P.T., et al. Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury. J. Neurosci. 2008, 28:13876-13888.
30. Arumugam T.V., Woodruff T.M., Lathia J.D., Selvaraj P.K., Mattson M.P., Taylor S.M. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience 2009, 158:1074-1089.
31. Ip W.K., Takahashi K., Ezekowitz R.A., Stuart L.M. Mannose-binding lectin and innate immunity. Immunol. Rev. 2009, 230:9-21.
32. Dommett R.M., Klein N., Turner M.W. Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens 2006, 68:193-209.
33. Osthoff M., Dean M.M., Baird P.N., Richardson A.J., Daniell M., Guymer R.H., et al. Association study of mannose-binding lectin levels and genetic variants in lectin pathway proteins with susceptibility to age-related macular degeneration: a case-control study. PLoS One 2015, 10.
34. Xue J., Liu A.H., Zhao B., Si M., Li Y.Q. Low levels of mannose-binding lectin at admission increase the risk of adverse neurological outcome in preterm infants: a 1-year follow-up study. J. Matern. Fetal Neonatal Med. 2015, 7:1-5.
35. Zhao Y., Lin W., Li Z., Lin J., Wang S., Zeng C., et al. High expression of mannose-binding lectin and the risk of vascular complications of diabetes: evidence from a meta-analysis. Diabetes Technol. Ther. 2015, 17:490-497.
36. Garred P. Mannose-binding lectin genetics: from a to Z. Biochem. Soc. Trans. 2008, 36:1461-1466.